肝功能障碍患者的生理学基础的药代动力学建模:博苏替尼暴露概况的变化是由改变的吸收或分布驱动的吗?
Chieko Muto1, Hannah M Jones2, Shinji Yamazaki2
1Clinical Pharmacology, Pfizer R&D Japan, Tokyo, Japan.
CPT: pharmacometrics & systems pharmacology
|January 14, 2026
概括
基于生理学的药动力学建模有助于了解肝功能障碍患者的博苏替尼暴露变化. 这种方法有助于优化慢性骨髓性白血病患者的治疗.
科学领域:
- 药理学 药理学是指药理学的学科.
- 药物新陈代谢 药物新陈代谢
- 临床药理学 临床药理学
背景情况:
- 博苏替尼是一种口服的Src/Abl氨酸激酶抑制剂,已批准用于费城染色体阳性慢性骨髓性白血病.
- 博苏替尼在体外被认为是P-glycoprotein (P-gp) 的基质.
- 人类对博苏替尼的新陈代谢主要涉及CYP3A4,尿道分泌有限.
研究的目的:
- 探索基于生理学的药理动力学 (PBPK) 建模的应用.
- 在肝功能受损的患者中阐明博苏替尼的药理学特征.
- 了解口服博苏替尼的不典型变化.
主要方法:
- 使用了基于生理学的药理动力学 (PBPK) 建模.
- 分析的重点是苏替尼,这是CYP3A和P-糖蛋白 (P-gp) 的基质.
- 这项研究检查了肝功能障碍患者群体的口服暴露.
主要成果:
- PBPK建模为理解博苏替尼的药理动力学提供了一个框架.
- 研究了肝功能障碍中口服暴露的非典型变化.
- 考虑了CYP3A和P-gp在博苏替尼布处置中的作用.
结论:
- PBPK建模是预测特定患者群体药物暴露的宝贵工具.
- 了解肝功能障碍中博苏替尼的药理动力学对于剂量优化至关重要.
- 使用PBPK的进一步研究可以为博苏替尼治疗的临床管理提供信息.
相关概念视频
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
277
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
277
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
212
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
212
Pharmacokinetic Models: Comparison and Selection Criterion
334
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
334
Model Approaches for Pharmacokinetic Data: Physiological Models
247
Physiological models in pharmacokinetics are instrumental in understanding the distribution and elimination of drugs within the body. These models describe the drug concentration within target organs, influenced by factors such as drug uptake, tissue volume, and blood flow. Drug uptake is governed by the partition coefficient, which signifies the drug concentration ratio in tissue to that in the blood. The blood flow rate to a specific tissue is expressed as Qt, and the rate of change in tissue...
247
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
253
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
253
Physiological Pharmacokinetic Models: Assumption with Protein Binding
211
Physiological models with protein binding in pharmacokinetics offer a sophisticated approach to understanding drug disposition. These models consider drug-protein interactions, enabling them to effectively predict drug concentrations in different organs and tissues. This precision aids in accurate drug dosing, providing a significant advantage over conventional models. A key process within these models is equilibration, which ensures that drug concentrations achieve a steady state within the...
211


